CN115996752B - 用于治疗癫痫的组合物和方法 - Google Patents

用于治疗癫痫的组合物和方法 Download PDF

Info

Publication number
CN115996752B
CN115996752B CN202180032987.3A CN202180032987A CN115996752B CN 115996752 B CN115996752 B CN 115996752B CN 202180032987 A CN202180032987 A CN 202180032987A CN 115996752 B CN115996752 B CN 115996752B
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
binding
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180032987.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN115996752A (zh
Inventor
J·T·帕斯
S·桑卡拉纳拉亚南
T·耶德诺克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gladstone Institutes
Annexon Inc
Original Assignee
Gladstone Institutes
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gladstone Institutes, Annexon Inc filed Critical Gladstone Institutes
Publication of CN115996752A publication Critical patent/CN115996752A/zh
Application granted granted Critical
Publication of CN115996752B publication Critical patent/CN115996752B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180032987.3A 2020-05-05 2021-05-05 用于治疗癫痫的组合物和方法 Active CN115996752B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063020245P 2020-05-05 2020-05-05
US63/020,245 2020-05-05
PCT/US2021/030930 WO2021242493A2 (en) 2020-05-05 2021-05-05 Compositions and methods for treating epilepsy

Publications (2)

Publication Number Publication Date
CN115996752A CN115996752A (zh) 2023-04-21
CN115996752B true CN115996752B (zh) 2025-04-01

Family

ID=78745740

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180032987.3A Active CN115996752B (zh) 2020-05-05 2021-05-05 用于治疗癫痫的组合物和方法

Country Status (8)

Country Link
US (1) US20240034775A1 (enExample)
EP (1) EP4146276A4 (enExample)
JP (1) JP2023524819A (enExample)
CN (1) CN115996752B (enExample)
AU (1) AU2021278819A1 (enExample)
CA (1) CA3177879A1 (enExample)
MX (1) MX2022013927A (enExample)
WO (1) WO2021242493A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105682740A (zh) * 2013-07-09 2016-06-15 安尼艾克松股份有限公司 抗-补体因子c1q抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912396T3 (es) * 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
PL3215527T3 (pl) * 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
JP6779876B2 (ja) * 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
IL309260B2 (en) * 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
US20190161535A1 (en) * 2016-05-09 2019-05-30 Annexon, Inc. Compositions and methods for treating spinal muscular atrophy
EP3487531A4 (en) * 2016-07-19 2020-03-25 Annexon, Inc. TREATMENT OF FRONTO-TEMPORAL DEMENTIA
CN112867394B9 (zh) * 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
MX2021004819A (es) * 2018-11-02 2021-06-08 Annexon Inc Composiciones y metodos para tratar lesiones cerebrales.
WO2020124013A1 (en) * 2018-12-13 2020-06-18 Gryphon Bio, Inc. Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105682740A (zh) * 2013-07-09 2016-06-15 安尼艾克松股份有限公司 抗-补体因子c1q抗体及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Complement factor C1q mediates sleep spindle loss and epileptic spikes after mild brain injury;Stephanie S Holden et al.;《Science》;20210910;第373卷(第6560期);文章号ebj2685 *
Enhanced classical complement pathway activation and altered phagocytosis signaling molecules in human epilepsy;Season K. Wyatt et al.;《Experimental neurology》;20170607;第295卷;第184-193页 *
Status epilepticus triggers long-lasting activation of complement C lq-C3 signaling in the hippocampus that correlates with seizure frequency in experimental epilepsy;Nicole D. Schartz et al.;《Neurobiology of disease》;20181023;第109(Pt A)卷;第163-173页 *

Also Published As

Publication number Publication date
CN115996752A (zh) 2023-04-21
WO2021242493A2 (en) 2021-12-02
JP2023524819A (ja) 2023-06-13
AU2021278819A1 (en) 2022-11-24
EP4146276A4 (en) 2024-08-14
CA3177879A1 (en) 2021-12-02
EP4146276A2 (en) 2023-03-15
WO2021242493A3 (en) 2022-06-09
US20240034775A1 (en) 2024-02-01
MX2022013927A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
US20250002567A1 (en) Anti-complement factor c1q fab fragments and uses thereof
RU2727911C2 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
JP2019514994A (ja) 脊髄性筋萎縮症を治療するための組成物及び方法
JP7809056B2 (ja) 血液障害を処置するための組成物及び方法
AU2017299579A1 (en) Compositions and methods for treating frontotemporal dementia
CN115996752A (zh) 用于治疗癫痫的组合物和方法
JP2023545501A (ja) 血液障害を処置するための組成物及び方法
HK40092865B (en) Compositions and methods for treating epilepsy
HK40092865A (en) Compositions and methods for treating epilepsy
CA3006092C (en) Anti-complement factor c1q fab fragments and uses thereof
HK40083120A (en) Anti-complement factor c1q fab fragments and uses thereof
HK40083120B (en) Anti-complement factor c1q fab fragments and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092865

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant